Connect Biopharma Holdings Ltd (CNTB) is now in the Fair zone, suggesting that its current forward PS ratio of 46251.92 is considered Fairly compared with the five-year average of -3.49. The fair price of Connect Biopharma Holdings Ltd (CNTB) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：2.57

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Connect Biopharma Holdings Ltd (CNTB) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Connect Biopharma Holdings Ltd (CNTB) has a current Price-to-Book (P/B) ratio of 2.54. Compared to its 3-year average P/B ratio of 0.79, the current P/B ratio is approximately 223.28% higher. Relative to its 5-year average P/B ratio of 1.03, the current P/B ratio is about 147.27% higher. Connect Biopharma Holdings Ltd (CNTB) has a Forward Free Cash Flow (FCF) yield of approximately -30.53%. Compared to its 3-year average FCF yield of -79.40%, the current FCF yield is approximately -61.55% lower. Relative to its 5-year average FCF yield of -85.56%, the current FCF yield is about -64.32% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CNTB competitors is 7710.14, providing a benchmark for relative valuation. Connect Biopharma Holdings Ltd Corp (CNTB.O) exhibits a P/S ratio of 46251.92, which is 499.88% above the industry average. Given its robust revenue growth of -98.69%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CNTB increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CNTB in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CNTB currently overvalued or undervalued?

What is Connect Biopharma Holdings Ltd (CNTB) fair value?

CNTB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Connect Biopharma Holdings Ltd (CNTB) is between to according to relative valuation method.

How does CNTB's valuation metrics compare to the industry average?

The average P/S ratio for CNTB's competitors is 7710.14, providing a benchmark for relative valuation. Connect Biopharma Holdings Ltd Corp (CNTB) exhibits a P/S ratio of 46251.92, which is 499.88% above the industry average. Given its robust revenue growth of -98.69%, this premium appears unsustainable.

What is the current P/B ratio for Connect Biopharma Holdings Ltd (CNTB) as of Mar 02 2026?

As of Mar 02 2026, Connect Biopharma Holdings Ltd (CNTB) has a P/B ratio of 2.54. This indicates that the market values CNTB at 2.54 times its book value.

What is the current FCF Yield for Connect Biopharma Holdings Ltd (CNTB) as of Mar 02 2026?

As of Mar 02 2026, Connect Biopharma Holdings Ltd (CNTB) has a FCF Yield of -30.53%. This means that for every dollar of Connect Biopharma Holdings Ltd's market capitalization, the company generates -30.53 cents in free cash flow.

What is the current Forward P/E ratio for Connect Biopharma Holdings Ltd (CNTB) as of Mar 02 2026?

As of Mar 02 2026, Connect Biopharma Holdings Ltd (CNTB) has a Forward P/E ratio of -1.96. This means the market is willing to pay $-1.96 for every dollar of Connect Biopharma Holdings Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Connect Biopharma Holdings Ltd (CNTB) as of Mar 02 2026?

As of Mar 02 2026, Connect Biopharma Holdings Ltd (CNTB) has a Forward P/S ratio of 46251.92. This means the market is valuing CNTB at $46251.92 for every dollar of expected revenue over the next 12 months.

CNTB Valuation